繁體中文
English
US
Japan
Korea
Panco
PharmaEssentia-Ropeginterferon alfa-2b,P1101,PV,polycythemia vera,new drug development,biologics,PIC/s GMP protein plant>
Mobile Button
Search>
About Us
Achievements
Executives
Partnership
Join Us
Locations
Privacy and Cookies Policy
Capabilities
R&D Center
Pipeline
Core Technology
R&D Focus
Manufacturing Site
Milestone
Facilities
Process and Critical Equipment
Focus
Hematology
P1101 in ET Phase III
Infectious Diseases
Clinical Study of P1101 in treatment of Chronic Hepatitis B
P1101 in HCV Phase III in Genotype 2 Study (A14-301)
Oncology
KX-ORAX-005 Oraxol in combination with Ramucirumab for Gastric, Gastro-esophageal or Esophageal Cancer
KX-ORAX-007 A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
PD-1 in HCC Phase I/II (IIT)
Dermatology
KX01 in Psoriasis
Publications
Patients & Healthcare
Patients & Healthcare Professionals
Medical Information
Resources
News
Latest News
Press Releases
Events
Investors
Financial Information
Shareholder’s Services
FAQ
Events & Presentations
Contact Us
ESG
Corporate Governance
Corporate Governance Structure
Board of Directors
Downloads
Contact
Language
繁體中文
English
日本語
Subsidiary
US
Japan
Korea
Panco
NEWS
Press Releases
Latest News
Press Releases
Events
2021
2020
2019
2018
2017
2016
2015
Dec 01
CEO Conversations XXV: Ms. Meredith Manning, General Manager, PharmaEssentia (6446 TT) US subsidiary
pharmaessentia
NEWS
Press Releases